Insmed (NASDAQ:INSM) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Insmed (NASDAQ:INSM) in a report issued on Monday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $228.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also recently issued reports on INSM. TD Cowen set a $241.00 price target on shares of Insmed in a report on Thursday, December 18th. Morgan Stanley set a $166.00 target price on shares of Insmed in a research report on Friday, February 20th. Guggenheim cut their target price on shares of Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Roth Mkm raised shares of Insmed to a “strong-buy” rating in a research report on Friday, January 23rd. Finally, UBS Group decreased their price target on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research note on Tuesday, January 6th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insmed has an average rating of “Buy” and an average price target of $205.57.

Insmed Price Performance

INSM stock opened at $144.60 on Monday. The stock’s 50 day moving average is $154.57 and its two-hundred day moving average is $166.22. Insmed has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a market capitalization of $31.17 billion, a PE ratio of -22.56 and a beta of 1.13. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. During the same quarter last year, the company posted ($1.32) earnings per share. The business’s quarterly revenue was up 152.6% compared to the same quarter last year. Analysts predict that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In other Insmed news, COO Roger Adsett sold 791 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total transaction of $123,530.47. Following the completion of the sale, the chief operating officer owned 106,810 shares in the company, valued at $16,680,517.70. The trade was a 0.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO William Lewis sold 10,699 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $146.03, for a total transaction of $1,562,374.97. Following the sale, the chief executive officer directly owned 301,185 shares in the company, valued at $43,982,045.55. This trade represents a 3.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 189,651 shares of company stock worth $31,784,545 in the last ninety days. 3.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Insmed

A number of large investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC grew its holdings in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the last quarter. CoreCap Advisors LLC bought a new stake in shares of Insmed in the 4th quarter worth approximately $27,000. Stone House Investment Management LLC acquired a new position in Insmed during the 3rd quarter valued at approximately $29,000. SBI Securities Co. Ltd. boosted its position in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares during the period. Finally, GraniteShares Advisors LLC bought a new position in Insmed during the 4th quarter worth $30,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.